We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effect of stage shift and immunotherapy treatment on lung cancer survival outcomes.
- Authors
Patel, Parth; Flores, Raja; Alpert, Naomi; Pyenson, Bruce; Taioli, Emanuela
- Abstract
Open in new tab Download slide OBJECTIVES Non-small-cell lung cancer mortality has declined at a faster rate than incidence due to multiple factors, including changes in smoking behaviour, early detection which shifts diagnosis, and novel therapies. Limited resources require that we quantify the contribution of early detection versus novel therapies in improving lung cancer survival outcomes. METHODS Non-small-cell lung cancer patients from the Surveillance, Epidemiology, and End Results-Medicare data were queried and divided into: (i) stage IV diagnosed in 2015 (n = 3774) and (ii) stage I–III diagnosed in 2010–2012 (n = 15 817). Multivariable Cox-proportional hazards models were performed to assess the independent association of immunotherapy or diagnosis at stage I/II versus III with survival. RESULTS Patients treated with immunotherapy had significantly better survival than those who did not (HRadj: 0.49, 95% confidence interval: 0.43–0.56), as did those diagnosed at stage I/II versus stage III (HRadj: 0.36, 95% confidence interval: 0.35–0.37). Patients on immunotherapy had a 10.7-month longer survival than those who were not. Stage I/II patients had an average survival benefit of 34 months, compared to stage III. If 25%% of stage IV patients not on immunotherapy received it, there would be a gain of 22 292 person-years survival per 100 000 diagnoses. A switch of only 25% from stage III to stage I/II would correspond to 70 833 person-years survival per 100 000 diagnoses. CONCLUSIONS In this cohort study, earlier stage at diagnosis contributed to life expectancy by almost 3 years, while gains from immunotherapy would contribute ½ year of survival. Given the relative affordability of early detection, risk reduction through increased screening should be optimized.
- Subjects
SURVIVAL rate; LUNG cancer; NON-small-cell lung carcinoma; CANCER treatment; IMMUNOTHERAPY
- Publication
European Journal of Cardio-Thoracic Surgery, 2023, Vol 64, Issue 2, p1
- ISSN
1010-7940
- Publication type
Article
- DOI
10.1093/ejcts/ezad203